The effect of metformin on Anti-Mullerian hormone levels in obese women

The effect of metformin on Anti-Mullerian hormone levels in obese women with polycystic ovarian syndrome : comparison of 2 doses

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107317165N1

Enrollment

Registered

2011-08-09

Start date

2011-08-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: In group 1 the patients will receive metformin 1500 mg-daily for six months. Intervention 2: In group 2 the patients will receive metformin 2500 mg-daily for six months.

Treatment - Drugs

In group 1 the patients will receive metformin 1500 mg-daily for six months

In group 2 the patients will receive metformin 2500 mg-daily for six months

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 80 infertile patient aged 20-35 years with pcos will include in the study in ARASH hospital of medical science from August 2011 till August 2013.the study was approved by the ethic committee of Tehran university of medical sciences and informed consent will obtain from each woman. Patients who have 2 of 3 criteria are diagnosed as polycystic ovarian syndrome: oligo-and/or anovulation; clinical/or biochemical signs of hyperandrogenism; polycystic ovarian syndrome ovaries. Exclusion criteria: congenital adrenal hyperplasia; Cushing syndrome; thyroid dysfunction; androgens secreting Tumors; diabetes; hyperprolactinemia and pregnancy. All patients have Body Mass index greater than 27 kg/m and normal liver and renal function tests. None of the subjects in both groups receive OCP or drugs for ovulation induction on day 3 of menstrual cycle, after an overnight fasting.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Androgen levels in obese women with PCOs. Timepoint: at the beginning and after 6 months. Method of measurement: by laboratory kit from blood sample.	—

Secondary

Measure	Time frame
SHBG levels in obese women with PCOs. Timepoint: at the beginning and after 6 months. Method of measurement: by laboratory kit from blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ladan Kashani

Tehran University of Medical sciences

Kashani_ladan@tums.ac.ir+98 21 7788 3195

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026